The most common genetic alteration present in sporadic or hereditary PEComas is a loss of function of the TSC1 (~ 27%) or TSC2 (~ 73%) genes, leading to the activation of mTOR signaling, which may represent a therapeutic target [11, 15, 20]. Here, TSC2 is linked to neoplasm with perivascular epithelioid cell differentiation.